Cargando…

Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study

BACKGROUND: Patients with antibody deficiencies depend on the presence of a variety of antibody specificities in intravenous immunoglobulin (IVIG) to ensure continued protection against pathogens. Few studies have examined levels of antibodies to specific pathogens in IVIG preparations and little is...

Descripción completa

Detalles Bibliográficos
Autores principales: Nobre, Fernanda Aimée, Gonzalez, Isabela Garrido da Silva, Simão, Raquel Maria, de Moraes Pinto, Maria Isabel, Costa-Carvalho, Beatriz Tavares
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074853/
https://www.ncbi.nlm.nih.gov/pubmed/24952415
http://dx.doi.org/10.1186/1471-2172-15-26
_version_ 1782323260218671104
author Nobre, Fernanda Aimée
Gonzalez, Isabela Garrido da Silva
Simão, Raquel Maria
de Moraes Pinto, Maria Isabel
Costa-Carvalho, Beatriz Tavares
author_facet Nobre, Fernanda Aimée
Gonzalez, Isabela Garrido da Silva
Simão, Raquel Maria
de Moraes Pinto, Maria Isabel
Costa-Carvalho, Beatriz Tavares
author_sort Nobre, Fernanda Aimée
collection PubMed
description BACKGROUND: Patients with antibody deficiencies depend on the presence of a variety of antibody specificities in intravenous immunoglobulin (IVIG) to ensure continued protection against pathogens. Few studies have examined levels of antibodies to specific pathogens in IVIG preparations and little is known about the specific antibody levels in patients under regular IVIG treatment. The current study determined the range of antibodies to tetanus, diphtheria, measles and varicella in IVIG products and the levels of these antibodies in patients undergoing IVIG treatment. METHODS: We selected 21 patients with primary antibody deficiencies who were receiving regular therapy with IVIG. Over a period of one year, we collected four blood samples from each patient (every 3 months), immediately before immunoglobulin infusion. We also collected samples from the IVIG preparation the patients received the month prior to blood collection. Antibody levels to tetanus, diphtheria, measles and varicella virus were measured in plasma and IVIG samples. Total IgG levels were determined in plasma samples. RESULTS: Antibody levels to tetanus, diphtheria, varicella virus and measles showed considerable variation in different IVIG lots, but they were similar when compared between commercial preparations. All patients presented with protective levels of antibodies specific for tetanus, measles and varicella. Some patients had suboptimal diphtheria antibody levels. There was a significant correlation between serum and IVIG antibodies to all pathogens, except tetanus. There was a significant correlation between diphtheria and varicella antibodies with total IgG levels, but there was no significant correlation with antibodies to tetanus or measles. CONCLUSIONS: The study confirmed the variation in specific antibody levels between batches of the same brand of IVIG. Apart from the most common infections to which these patients are susceptible, health care providers must be aware of other vaccine preventable diseases, which still exist globally.
format Online
Article
Text
id pubmed-4074853
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40748532014-07-01 Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study Nobre, Fernanda Aimée Gonzalez, Isabela Garrido da Silva Simão, Raquel Maria de Moraes Pinto, Maria Isabel Costa-Carvalho, Beatriz Tavares BMC Immunol Research Article BACKGROUND: Patients with antibody deficiencies depend on the presence of a variety of antibody specificities in intravenous immunoglobulin (IVIG) to ensure continued protection against pathogens. Few studies have examined levels of antibodies to specific pathogens in IVIG preparations and little is known about the specific antibody levels in patients under regular IVIG treatment. The current study determined the range of antibodies to tetanus, diphtheria, measles and varicella in IVIG products and the levels of these antibodies in patients undergoing IVIG treatment. METHODS: We selected 21 patients with primary antibody deficiencies who were receiving regular therapy with IVIG. Over a period of one year, we collected four blood samples from each patient (every 3 months), immediately before immunoglobulin infusion. We also collected samples from the IVIG preparation the patients received the month prior to blood collection. Antibody levels to tetanus, diphtheria, measles and varicella virus were measured in plasma and IVIG samples. Total IgG levels were determined in plasma samples. RESULTS: Antibody levels to tetanus, diphtheria, varicella virus and measles showed considerable variation in different IVIG lots, but they were similar when compared between commercial preparations. All patients presented with protective levels of antibodies specific for tetanus, measles and varicella. Some patients had suboptimal diphtheria antibody levels. There was a significant correlation between serum and IVIG antibodies to all pathogens, except tetanus. There was a significant correlation between diphtheria and varicella antibodies with total IgG levels, but there was no significant correlation with antibodies to tetanus or measles. CONCLUSIONS: The study confirmed the variation in specific antibody levels between batches of the same brand of IVIG. Apart from the most common infections to which these patients are susceptible, health care providers must be aware of other vaccine preventable diseases, which still exist globally. BioMed Central 2014-06-21 /pmc/articles/PMC4074853/ /pubmed/24952415 http://dx.doi.org/10.1186/1471-2172-15-26 Text en Copyright © 2014 Nobre et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Nobre, Fernanda Aimée
Gonzalez, Isabela Garrido da Silva
Simão, Raquel Maria
de Moraes Pinto, Maria Isabel
Costa-Carvalho, Beatriz Tavares
Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
title Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
title_full Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
title_fullStr Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
title_full_unstemmed Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
title_short Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
title_sort antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074853/
https://www.ncbi.nlm.nih.gov/pubmed/24952415
http://dx.doi.org/10.1186/1471-2172-15-26
work_keys_str_mv AT nobrefernandaaimee antibodylevelstotetanusdiphtheriameaslesandvaricellainpatientswithprimaryimmunodeficiencyundergoingintravenousimmunoglobulintherapyaprospectivestudy
AT gonzalezisabelagarridodasilva antibodylevelstotetanusdiphtheriameaslesandvaricellainpatientswithprimaryimmunodeficiencyundergoingintravenousimmunoglobulintherapyaprospectivestudy
AT simaoraquelmaria antibodylevelstotetanusdiphtheriameaslesandvaricellainpatientswithprimaryimmunodeficiencyundergoingintravenousimmunoglobulintherapyaprospectivestudy
AT demoraespintomariaisabel antibodylevelstotetanusdiphtheriameaslesandvaricellainpatientswithprimaryimmunodeficiencyundergoingintravenousimmunoglobulintherapyaprospectivestudy
AT costacarvalhobeatriztavares antibodylevelstotetanusdiphtheriameaslesandvaricellainpatientswithprimaryimmunodeficiencyundergoingintravenousimmunoglobulintherapyaprospectivestudy